Q3 Biotech Venture Investing Makes a Boisterous Leap

Life Sciences Tools & DiagnosticsMedical DevicesBiotechnology / Pharmaceuticals

Source: FierceBiotech, John Carroll (10/19/12)

"Using the figures provided by Thomson Reuters, the quarterly report concluded that total life sciences venture deals topped $1.7B in 181 deals in the third quarter—a bit more than a quarter of all investments tracked during the period."

The life sciences industry gained a blast of good news on the venture front today. The National Venture Capital Association and PricewaterhouseCoopers outlined a buoyant set of numbers for the industry, noting a nice spike in the amount invested in biotechs as well as the number of deals completed.

Using the figures provided by Thomson Reuters, the quarterly report concluded that total life sciences venture deals topped $1.7 billion in 181 deals in the third quarter—a bit more than a quarter of all investments tracked during the period. Excluding medical devices, biotech gained $1.2 billion of that for 116 companies, a hefty 64% increase in dollars and a 22% jump in deals. . .View Full Article

LA Biotech's Lower Revenue Will Be Short Lived
Source: Dr. Jonathan Aschoff (04/17/2024)

While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note.

Healthcare Co. Welcomes Possible AI Funding Effort in Canada
Source: Streetwise Reports (04/09/2024)

Canadian artificial intelligence (AI) and machine learning healthcare company Treatment.com AI Inc. is using AI to positively disrupt the healthcare sector. Canada is planning to fund the industry in a big way.

Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out
Source: Streetwise Reports (04/08/2024)

After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high.

Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Source: Streetwise Reports (03/27/2024)

Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.

AI Co. Funded To Develop AI Approach to Health Equity
Source: Streetwise Reports (03/27/2024)

Treatment.com AI Inc. announced it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. Read on to see the medical need for this type of service and why one technical analysts is optimistic about this stock.